EUCTR2004-005093-24-LT进行中（未招募）不适用
Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatment
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 533
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Provision of informed consent
- •2.Patients who have completed a preceding gefitinib study and in the opinion of the investigator may benefit from gefitinib treatment. Only patients completing the studies listed below are eligible for enrolment in this open label extension protocol.
- •1839IL/0709 (250mg dosing)
- •1839IL/0710 (250mg dosing)
- •3.No more than 14 days have elapsed between the patient completing the preceding gefitinib clinical study and beginning of this study except when agreed by the AstraZeneca physician.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Known severe hypersensitivity to gefitinib or any of the excipients of this product
- •2.Pregnancy or breast feeding (women of child-bearing potential). Women of childbearing potential must practice acceptable methods of birth control to prevent pregnancy
- •3.Any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded)
- •4.In the opinion of the investigator, any evidence of severe or uncontrolled systemic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease).
- •5.Withdrawal, at any time, from the preceding gefitinib study.
- •6.Concomitant use of phenytoin, carbamazepine, rifampicin, barbiturates, or St John’s Wort
- •7.Evidence of any significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the study
- •8.Involvement in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the investigational site)
- •9.Previous enrolment in the present study.
研究者
相似试验
进行中（未招募）
不适用
Multicentre, open label, extension study of treatment with gefitinib (IRESSA) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatmentThis trial is for patients with advanced non-small cell lung cancer who have completed a preceding gefitinib trial (ZD1839IL0709 or ZD1839IL0710) and in the opinion of the investigator may benefit from gefitinib treatmentEUCTR2004-005093-24-LVAstraZeneca AB533
进行中（未招募）
不适用
Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatmentThis trial is for patients with advanced non-small cell lung cancer who have completed a preceding gefitinib trial (ZD1839IL0709 or ZD1839IL0710) and in the opinion of the investigator may benefit from gefitinib treatmentEUCTR2004-004229-93-EEAstraZeneca AB533
进行中（未招募）
1 期
Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatmentEUCTR2004-004229-93-HUAstraZeneca AB533
进行中（未招募）
不适用
Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatmentEUCTR2004-005093-24-HUAstraZeneca AB533
进行中（未招募）
不适用
Multicentre, open label, extension study of treatment with gefitinib (IRESSA™) for patients completing other gefitinib clinical studies who may benefit from gefitinib treatmentThis trial is for patients with advanced non-small cell lung cancer who have completed a preceding gefitinib trial (ZD1839IL0709 or ZD1839IL0710) and in the opinion of the investigator may benefit from gefitinib treatmentEUCTR2004-005093-24-ATAstraZeneca Österreich GmbH533